Organon & Co., headquartered in Jersey City, develops innovative health solutions in women’s health, biosimilars, and established brands, employing 10,000 people and operating six manufacturing facilities worldwide. The company went public on May 14, 2021, and offers products like Nexplanon and Follistim AQ through various distribution channels.